biote Corp. Announces 2024 Annual Meeting of Stockholders on May 21
Ticker: BTMD · Form: DEF 14A · Filed: Apr 11, 2024 · CIK: 1819253
Sentiment: neutral
Topics: Annual Meeting, Proxy Statement, Director Election, Auditor Ratification, biote Corp.
TL;DR
<b>biote Corp. will hold its 2024 Annual Meeting of Stockholders virtually on May 21, 2024, to elect directors and ratify auditors.</b>
AI Summary
biote Corp. (BTMD) filed a Proxy Statement (DEF 14A) with the SEC on April 11, 2024. Annual meeting to be held virtually on May 21, 2024, at 10:00 a.m. Central Time. Stockholders of record as of April 1, 2024, are eligible to attend and vote. Three Class II directors, Steven J. Heyer, S. Mark Cone, and Debra L. Morris, will be elected. Directors will serve until the 2027 annual meeting. Deloitte & Touche LLP will be ratified as the independent registered public accounting firm for fiscal year 2024.
Why It Matters
For investors and stakeholders tracking biote Corp., this filing contains several important signals. The election of directors and ratification of auditors are key governance activities that impact the company's strategic direction and financial oversight. The virtual format allows for broader participation from stockholders regardless of location, promoting engagement.
Risk Assessment
Risk Level: low — biote Corp. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational changes indicated.
Analyst Insight
Stockholders should review the director nominees and auditor ratification proposals to make informed voting decisions.
Key Numbers
- May 21, 2024 — Annual Meeting Date (Date of the 2024 annual meeting of stockholders)
- 10:00 a.m. Central Time — Annual Meeting Time (Time of the 2024 annual meeting of stockholders)
- April 1, 2024 — Record Date (Stockholders of record on this date are eligible to attend and vote)
- 3 — Directors to be Elected (Number of Class II directors to be elected)
- 2027 — Director Term End (Year until which elected directors will serve)
Key Players & Entities
- biote Corp. (company) — Registrant name
- May 21, 2024 (date) — Date of Annual Meeting
- Steven J. Heyer (person) — Director nominee
- S. Mark Cone (person) — Director nominee
- Debra L. Morris (person) — Director nominee
- Deloitte & Touche LLP (company) — Independent registered public accounting firm
- April 1, 2024 (date) — Record Date for Annual Meeting
- BTMD (company) — Ticker symbol for virtual meeting access
FAQ
When did biote Corp. file this DEF 14A?
biote Corp. filed this Proxy Statement (DEF 14A) with the SEC on April 11, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by biote Corp. (BTMD).
Where can I read the original DEF 14A filing from biote Corp.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by biote Corp..
What are the key takeaways from biote Corp.'s DEF 14A?
biote Corp. filed this DEF 14A on April 11, 2024. Key takeaways: Annual meeting to be held virtually on May 21, 2024, at 10:00 a.m. Central Time.. Stockholders of record as of April 1, 2024, are eligible to attend and vote.. Three Class II directors, Steven J. Heyer, S. Mark Cone, and Debra L. Morris, will be elected..
Is biote Corp. a risky investment based on this filing?
Based on this DEF 14A, biote Corp. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational changes indicated.
What should investors do after reading biote Corp.'s DEF 14A?
Stockholders should review the director nominees and auditor ratification proposals to make informed voting decisions. The overall sentiment from this filing is neutral.
How does biote Corp. compare to its industry peers?
biote Corp. operates in the biopharmaceutical sector, focusing on hormone therapy and related products.
Are there regulatory concerns for biote Corp.?
The filing is a standard DEF 14A, indicating compliance with SEC proxy solicitation rules.
Industry Context
biote Corp. operates in the biopharmaceutical sector, focusing on hormone therapy and related products.
Regulatory Implications
The filing is a standard DEF 14A, indicating compliance with SEC proxy solicitation rules.
What Investors Should Do
- Review the biographies and qualifications of the director nominees.
- Evaluate the rationale for ratifying Deloitte & Touche LLP as the independent auditor.
- Attend the virtual meeting or submit proxy votes by the deadline.
Key Dates
- 2024-05-21: Annual Meeting of Stockholders — Election of directors and ratification of auditors
- 2024-04-01: Record Date — Determines eligibility to vote and attend the annual meeting
Year-Over-Year Comparison
This is a DEF 14A filing for the annual meeting, distinct from previous operational or financial reports.
Filing Stats: 4,991 words · 20 min read · ~17 pages · Grade level 11.4 · Accepted 2024-04-11 16:16:28
Key Financial Figures
- $0.0001 — ares of Class A common stock, par value $0.0001 per share ( Class A common stock ), and
Filing Documents
- d688560ddef14a.htm (DEF 14A) — 357KB
- g688560g22n44.jpg (GRAPHIC) — 62KB
- g688560page02a.jpg (GRAPHIC) — 4KB
- g688560page02b.jpg (GRAPHIC) — 31KB
- g688560page02c.jpg (GRAPHIC) — 2KB
- g688560page02d.jpg (GRAPHIC) — 1KB
- g688560page02e.jpg (GRAPHIC) — 1KB
- g688560page02f.jpg (GRAPHIC) — 2KB
- g688560page03b.jpg (GRAPHIC) — 1KB
- g688560page03c.jpg (GRAPHIC) — 1KB
- g688560page05.jpg (GRAPHIC) — 3KB
- 0001193125-24-093250.txt ( ) — 508KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 23 DIRECTOR COMPENSATION 29 EQUITY COMPENSATION PLAN INFORMATION 31
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 32 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 35 OTHER MATTERS 39 Table of Contents 1875 W. Walnut Hill Ln, #100 Irving, TX 75038 PROXY FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held on Tuesday, May 21, 2024 at 10:00 a.m. Central Time QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why have these proxy materials been made available to me? This proxy statement and the enclosed form of proxy are being furnished in connection with the solicitation of proxies on behalf of the Board of Directors (the Board of Directors or Board ) of biote Corp., a Delaware corporation ( Biote , Company , we , us and our ), for use at our 2024 annual meeting of stockholders or any adjournments or postponements thereof (the Annual Meeting ). The Annual Meeting will be held virtually on Tuesday, May 21, 2024 at 10:00 a.m. Central Time via live webcast. You will be able to attend the virtual Annual Meeting, vote your shares electronically and submit your questions during the live webcast of the meeting by visiting www.proxydocs.com/BTMD and entering your control number located on your proxy card or voting instruction form. The proxy materials, including this proxy statement and the Annual Report on Form 10-K for the year ended December 31, 2023, will be made available online at www.proxydocs.com/BTMD and mailed to stockholders on or about April 11, 2024. How do I attend and participate in the Annual Meeting? You are entitled to attend the Annual Meeting only if you were a stockholder at the close of business on April 1, 2024 (the Record Date ) or if you hold a valid proxy to vote at the Annual Meeting. We will be hosting the Annual Meeting via the Internet. You will not be able to attend the Annual Meeting in person. Any stockholder can listen to and participate in the Annual Meeting via live webcast at www.proxydocs.com/BTMD. In